Rafael Amado is EVP of R&D of Allogene Therapeutics, Inc.. Currently has a direct ownership of 541,946 shares of ALLO, which is worth approximately $1.39 Million. The most recent transaction as insider was on Oct 07, 2022, when has been sold 8,464 shares (Common Stock) at a price of $11.83 per share, resulting in proceeds of $100,129. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 542K
0% 3M change
0% 12M change
Total Value Held $1.39 Million

Rafael Amado Transaction History

Date Transaction Value Shares Traded Shares Held Form
Oct 07 2022
SELL
Payment of exercise price or tax liability
$100,129 $11.83 p/Share
8,464 Reduced 1.54%
541,946 Common Stock
Oct 07 2022
BUY
Grant, award, or other acquisition
-
19,120 Added 3.36%
550,410 Common Stock
Oct 03 2022
SELL
Payment of exercise price or tax liability
$99,186 $11.06 p/Share
8,968 Reduced 1.66%
531,290 Common Stock
Aug 02 2022
SELL
Open market or private sale
$23,940 $11.97 p/Share
2,000 Reduced 0.37%
540,257 Common Stock
Jul 05 2022
SELL
Open market or private sale
$22,880 $11.44 p/Share
2,000 Reduced 0.37%
542,257 Common Stock
Jun 21 2022
SELL
Open market or private sale
$22,360 $11.18 p/Share
2,000 Reduced 0.37%
544,257 Common Stock
May 19 2022
SELL
Open market or private sale
$85,100 $7.4 p/Share
11,500 Reduced 2.06%
546,257 Common Stock
Mar 23 2022
BUY
Grant, award, or other acquisition
-
237,358 Added 29.86%
557,477 Common Stock
Mar 15 2022
SELL
Open market or private sale
$39,853 $7.71 p/Share
5,169 Reduced 1.59%
320,119 Common Stock
Oct 01 2021
SELL
Open market or private sale
$280,195 $24.35 p/Share
11,507 Reduced 3.43%
323,928 Common Stock
May 18 2021
BUY
Grant, award, or other acquisition
-
200,534 Added 37.42%
335,435 Common Stock
Mar 26 2021
BUY
Grant, award, or other acquisition
-
24,866 Added 15.56%
134,901 Common Stock
Mar 15 2021
SELL
Open market or private sale
$106,464 $38.05 p/Share
2,798 Reduced 2.48%
110,035 Common Stock
Oct 07 2020
SELL
Open market or private sale
$651,597 $39.4 p/Share
16,538 Reduced 12.9%
111,677 Common Stock
Oct 01 2020
SELL
Open market or private sale
$354,680 $36.37 p/Share
9,752 Reduced 7.07%
128,215 Common Stock

Also insider at

ZLAB
Zai Lab Ltd Healthcare
PSTX
Poseida Therapeutics, Inc. Healthcare
RA

Rafael Amado

EVP of R&D
South San Francisco, CA

Track Institutional and Insider Activities on ALLO

Follow Allogene Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALLO shares.

Notify only if

Insider Trading

Get notified when an Allogene Therapeutics, Inc. insider buys or sells ALLO shares.

Notify only if

News

Receive news related to Allogene Therapeutics, Inc.

Track Activities on ALLO